C. Viner

1.6k total citations
34 papers, 1.2k citations indexed

About

C. Viner is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, C. Viner has authored 34 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 14 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in C. Viner's work include Multiple Myeloma Research and Treatments (21 papers), Cancer Treatment and Pharmacology (11 papers) and Cancer therapeutics and mechanisms (4 papers). C. Viner is often cited by papers focused on Multiple Myeloma Research and Treatments (21 papers), Cancer Treatment and Pharmacology (11 papers) and Cancer therapeutics and mechanisms (4 papers). C. Viner collaborates with scholars based in United Kingdom, Canada and United States. C. Viner's co-authors include Peter J. Selby, David Cunningham, J. S. Malpas, S Milan, Martin Gore, R Powles, Tamas Hickish, M. Nicolson, T J McElwain and M Meldrum and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Gut.

In The Last Decade

C. Viner

33 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Viner United Kingdom 17 812 541 519 141 91 34 1.2k
Annette Juul Vangsted Denmark 21 692 0.9× 622 1.1× 598 1.2× 312 2.2× 45 0.5× 90 1.3k
Karel Hählen Netherlands 17 535 0.7× 959 1.8× 389 0.7× 447 3.2× 110 1.2× 31 2.1k
Richard J. Rosenbluth United States 16 94 0.1× 180 0.3× 386 0.7× 61 0.4× 151 1.7× 26 945
Frances Bennett United Kingdom 8 179 0.2× 285 0.5× 354 0.7× 388 2.8× 41 0.5× 13 934
Mark Goodman United States 16 287 0.4× 260 0.5× 261 0.5× 137 1.0× 33 0.4× 52 903
Vanessa Taylor United States 17 122 0.2× 421 0.8× 166 0.3× 382 2.7× 56 0.6× 56 1.1k
Ashley Rosko United States 20 584 0.7× 461 0.9× 713 1.4× 110 0.8× 43 0.5× 122 1.4k
David P. Sheridan Canada 13 157 0.2× 265 0.5× 102 0.2× 90 0.6× 50 0.5× 32 687
Bin Zhong China 18 175 0.2× 394 0.7× 337 0.6× 757 5.4× 60 0.7× 29 1.5k
Diana Abbott United States 19 750 0.9× 745 1.4× 258 0.5× 99 0.7× 180 2.0× 62 1.8k

Countries citing papers authored by C. Viner

Since Specialization
Citations

This map shows the geographic impact of C. Viner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Viner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Viner more than expected).

Fields of papers citing papers by C. Viner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Viner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Viner. The network helps show where C. Viner may publish in the future.

Co-authorship network of co-authors of C. Viner

This figure shows the co-authorship network connecting the top 25 collaborators of C. Viner. A scholar is included among the top collaborators of C. Viner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Viner. C. Viner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mowitz, Meredith, et al.. (2021). Unbiasing costs? An appraisal of economic assessment alongside randomized trials in neonatology. Seminars in Perinatology. 45(3). 151391–151391. 5 indexed citations
2.
Viner, C., et al.. (2019). Perspectives on fertility preservation and parenthood among transgender youth and their parents. Archives of Disease in Childhood. 104(8). 739–744. 71 indexed citations
3.
Chadi, Nicholas, et al.. (2018). Can the Mindful Awareness and Resilience Skills for Adolescents (MARS-A) Program Be Provided Online? Voices from the Youth. Children. 5(9). 115–115. 13 indexed citations
4.
Chadi, Nicholas, et al.. (2017). In-Person Versus eHealth Mindfulness-Based Intervention for Adolescents With Chronic Illness: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 6(11). e241–e241. 9 indexed citations
5.
Kirpalani, Haresh, C. Viner, Roger F. Soll, et al.. (2017). Do trials reduce uncertainty? Assessing impact through cumulative meta-analysis of neonatal RCTs. Journal of Perinatology. 37(11). 1215–1219. 3 indexed citations
6.
Cunningham, David, R Powles, J. S. Malpas, et al.. (1998). A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results. British Journal of Haematology. 102(2). 495–502. 124 indexed citations
7.
8.
Powles, R, Noopur Raje, S Milan, et al.. (1997). Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplantation. 20(6). 435–443. 55 indexed citations
9.
Powles, R, Noopur Raje, C Horton, et al.. (1996). Comparison of Interferon Tolerance after Autologous Bone Marrow or Peripheral Blood Stem Cell Transplants for Myeloma Patients who have Responded to Induction Therapy. Leukemia & lymphoma. 21(5-6). 421–427. 11 indexed citations
10.
Milan, S, David Cunningham, M. Nicolson, et al.. (1996). High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease - a pragmatic prognostic index. British Journal of Cancer. 73(10). 1272–1277. 15 indexed citations
11.
Cunningham, David, Luis Paz‐Ares, Martin Gore, et al.. (1994). High-dose melphalan for multiple myeloma: long-term follow-up data.. Journal of Clinical Oncology. 12(4). 764–768. 70 indexed citations
12.
Cunningham, David, Luis Paz‐Ares, S Milan, et al.. (1994). High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.. Journal of Clinical Oncology. 12(4). 759–763. 174 indexed citations
13.
Tilby, M.J., David R. Newell, Peter J. Selby, C. Viner, & Christopher Dean. (1993). Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy. European Journal of Cancer. 29(5). 681–686. 18 indexed citations
14.
Mansi, Janine, et al.. (1992). High-dose busulfan in patients with myeloma.. Journal of Clinical Oncology. 10(10). 1569–1573. 27 indexed citations
15.
Jones, Alison L., et al.. (1992). A randomised phase II study of carmustine alone or in combination with tomour necrosis factor in patients with advanced melanoma. Cancer Chemotherapy and Pharmacology. 30(1). 73–76. 8 indexed citations
16.
Selby, Peter J., M. Gore, Timothy Perren, et al.. (1992). High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease. European Journal of Cancer. 28(8-9). 1396–1400. 12 indexed citations
17.
Viner, C., et al.. (1990). Ondansetron ? a new safe and effective antiemetic in patients receiving high-dose melphalan. Cancer Chemotherapy and Pharmacology. 25(6). 449–453. 18 indexed citations
18.
Jones, Alison, et al.. (1990). Tumour necrosis factor, cholestatic jaundice, and chronic liver disease.. Gut. 31(8). 938–939. 43 indexed citations
19.
Selby, Peter J., Garry Forgeson, M Meldrum, et al.. (1988). The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's hospital studies. Hematological Oncology. 6(2). 173–179. 28 indexed citations
20.
Forgeson, Garry, et al.. (1988). Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. British Journal of Cancer. 58(4). 469–473. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annette Juul Vangsted Breakdown of academic impact, for papers by Karel Hählen Breakdown of academic impact, for papers by Richard J. Rosenbluth Breakdown of academic impact, for papers by Frances Bennett Breakdown of academic impact, for papers by Mark Goodman Breakdown of academic impact, for papers by Vanessa Taylor Breakdown of academic impact, for papers by Ashley Rosko Breakdown of academic impact, for papers by David P. Sheridan Breakdown of academic impact, for papers by Bin Zhong Breakdown of academic impact, for papers by Diana Abbott
Rankless by CCL
2026